AstraZeneca and the Center of Excellence for Medical Genomics, Chulalongkorn University

9 December 2024

AstraZeneca and the Center of Excellence for Medical Genomics, Chulalongkorn University Forge Partnership to Drive Next-Generation Sequencing (NGS) Innovation
for Breakthroughs in Rare Disease Detection

Bangkok – AstraZeneca (Thailand) Limited has signed a Memorandum of Understanding (MoU) with the Center of Excellence for Medical Genomics at the Faculty of Medicine, Chulalongkorn University. This strategic collaboration aims to advance Next Generation Sequencing (NGS) technology, enhancing the detection of genetic mutations linked to rare diseases and raising awareness among the Thai population. Currently, rare diseases affect approximately 5% of Thailand’s population, equating to around 3.5 million individuals.

Mr. Roman Ramos, Country President of AstraZeneca Thailand and Frontier Markets, stated, “This collaboration seeks to drive innovation and elevate the standards of care for rare disease patients in Thailand by increasing public awareness of the importance of genetic risk screening. Diagnosing rare diseases remains challenging for general practitioners due to complex symptoms and the limited availability of specialists in Thailand. By upgrading NGS technology, we can empower doctors to initiate treatment planning at an earlier stage. Additionally, AstraZeneca will play a pivotal role in genetic counselling, prevention, and provide training and networking opportunities on both national and international scales, helping to bring rare disease diagnosis and treatment in Thailand to global standards.”

Prof. Vorasuk Shotelersuk, Professor of Pediatrics, Faculty of Medicine, Chulalongkorn University, remarked, “Currently, the Center of Excellence for Medical Genomics excels as the leading institution in Thailand equipped with NGS technology for detecting genetic abnormalities. The treatment of rare genetic diseases is largely reactive, focusing on managing symptoms after diagnosis. However, advancements in state-of-the-art medical innovations will enable early detection of genetic abnormalities, not only benefiting those at risk but also paving the way for further research to mitigate genetic disease risks in the future. This progress will ultimately lead to the development of treatments targeting diseases at the causal gene level.”

Although individually rare, collectively, rare diseases—comprising at least 7,000 distinct disorders—are not uncommon. The impact is profound, affecting patients and their families deeply, as these conditions occur by chance, not by choice, and are often incurable. Treatment typically focuses on managing symptoms to prevent progression. However, the use of NGS technology to diagnose genetic abnormalities offers new hope, enabling patients and doctors to plan proactive treatments together while advancing research into preventive measures. Individuals at risk can access testing at the Center of Excellence for Medical Genomics, Faculty of Medicine, Chulalongkorn University, and the King Chulalongkorn Memorial Hospital, part of the Thai Red Cross Society.

This significant collaboration aligns with AstraZeneca's mission to enhance quality of life in Thailand and worldwide through pioneering medical innovations with global partners. AstraZeneca’s commitment to sustainable health for all remains the highest priority.